Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer
Mutations of the p53 gene are the most common genomic alterations associated with triple-negative breast cancer (TNBC) and are reported in 60–88% cases. Despite the high incidence of such mutations, there is no consensus about the clinical application of p53 detection in breast cancer management. Th...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-12-01
|
Series: | Kaohsiung Journal of Medical Sciences |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1607551X18300512 |
id |
doaj-d0915867a940421f9de00b88181d5459 |
---|---|
record_format |
Article |
spelling |
doaj-d0915867a940421f9de00b88181d54592020-11-25T00:21:14ZengWileyKaohsiung Journal of Medical Sciences1607-551X2018-12-013412663672Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancerSoo Youn Bae0Seung Pil Jung1Se Kyung Lee2Jonghan Yu3Jeong Eon Lee4Seok Won Kim5Seok Jin Nam6Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South KoreaDepartment of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South KoreaDepartment of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South KoreaDepartment of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South KoreaDepartment of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Corresponding author. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Kangnam-gu, Seoul, 135-710, South Korea.Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South KoreaDepartment of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South KoreaMutations of the p53 gene are the most common genomic alterations associated with triple-negative breast cancer (TNBC) and are reported in 60–88% cases. Despite the high incidence of such mutations, there is no consensus about the clinical application of p53 detection in breast cancer management. This study investigates the prognostic value of immunohistochemically detected p53 in TNBC patients who received adjuvant chemotherapy. We reviewed the clinicopathologic features of 1088 TNBC patients who received curative surgery and adjuvant chemotherapy. Immunohistochemically, nuclear staining of >10% was defined as p53 “positive.” Of the total 1088 TNBC patients, 709 (65.2%) had no lymph node metastasis (N0). Among the N0 patients, 408 (57.5%) were p53- positive (p53+), and 301 (42.5%) were p53- negative (p53-). p53 + tumors showed a tendency for better breast cancer-specific survival (BCSS, p = 0.052) and overall survival (OS, p = 0.079) compared to p53- tumors. In multivariate analysis, p53 + tumors showed significantly better BCSS (p53 + vs. p53-; HR 2.8, 95% confidence interval: 1.1–7.3, p = 0.034); however, in TNBC patients with lymph node metastasis, there was no correlation between p53 status, clinicopathologic characteristics, and survival. Consequently, in TNBC patients who received adjuvant chemotherapy, immunohistochemical p53 expression was associated with better BCSS in N0 patients. Keywords: Triple-negative breast cancer, Chemotherapy, p53, Immunohistochemistry, Survivalhttp://www.sciencedirect.com/science/article/pii/S1607551X18300512 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Soo Youn Bae Seung Pil Jung Se Kyung Lee Jonghan Yu Jeong Eon Lee Seok Won Kim Seok Jin Nam |
spellingShingle |
Soo Youn Bae Seung Pil Jung Se Kyung Lee Jonghan Yu Jeong Eon Lee Seok Won Kim Seok Jin Nam Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer Kaohsiung Journal of Medical Sciences |
author_facet |
Soo Youn Bae Seung Pil Jung Se Kyung Lee Jonghan Yu Jeong Eon Lee Seok Won Kim Seok Jin Nam |
author_sort |
Soo Youn Bae |
title |
Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer |
title_short |
Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer |
title_full |
Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer |
title_fullStr |
Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer |
title_full_unstemmed |
Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer |
title_sort |
prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer |
publisher |
Wiley |
series |
Kaohsiung Journal of Medical Sciences |
issn |
1607-551X |
publishDate |
2018-12-01 |
description |
Mutations of the p53 gene are the most common genomic alterations associated with triple-negative breast cancer (TNBC) and are reported in 60–88% cases. Despite the high incidence of such mutations, there is no consensus about the clinical application of p53 detection in breast cancer management. This study investigates the prognostic value of immunohistochemically detected p53 in TNBC patients who received adjuvant chemotherapy. We reviewed the clinicopathologic features of 1088 TNBC patients who received curative surgery and adjuvant chemotherapy. Immunohistochemically, nuclear staining of >10% was defined as p53 “positive.” Of the total 1088 TNBC patients, 709 (65.2%) had no lymph node metastasis (N0). Among the N0 patients, 408 (57.5%) were p53- positive (p53+), and 301 (42.5%) were p53- negative (p53-). p53 + tumors showed a tendency for better breast cancer-specific survival (BCSS, p = 0.052) and overall survival (OS, p = 0.079) compared to p53- tumors. In multivariate analysis, p53 + tumors showed significantly better BCSS (p53 + vs. p53-; HR 2.8, 95% confidence interval: 1.1–7.3, p = 0.034); however, in TNBC patients with lymph node metastasis, there was no correlation between p53 status, clinicopathologic characteristics, and survival. Consequently, in TNBC patients who received adjuvant chemotherapy, immunohistochemical p53 expression was associated with better BCSS in N0 patients. Keywords: Triple-negative breast cancer, Chemotherapy, p53, Immunohistochemistry, Survival |
url |
http://www.sciencedirect.com/science/article/pii/S1607551X18300512 |
work_keys_str_mv |
AT sooyounbae prognosticvalueofimmunohistochemicallydetectedp53inadjuvantchemotherapytreatedtriplenegativebreastcancer AT seungpiljung prognosticvalueofimmunohistochemicallydetectedp53inadjuvantchemotherapytreatedtriplenegativebreastcancer AT sekyunglee prognosticvalueofimmunohistochemicallydetectedp53inadjuvantchemotherapytreatedtriplenegativebreastcancer AT jonghanyu prognosticvalueofimmunohistochemicallydetectedp53inadjuvantchemotherapytreatedtriplenegativebreastcancer AT jeongeonlee prognosticvalueofimmunohistochemicallydetectedp53inadjuvantchemotherapytreatedtriplenegativebreastcancer AT seokwonkim prognosticvalueofimmunohistochemicallydetectedp53inadjuvantchemotherapytreatedtriplenegativebreastcancer AT seokjinnam prognosticvalueofimmunohistochemicallydetectedp53inadjuvantchemotherapytreatedtriplenegativebreastcancer |
_version_ |
1725363233603190784 |